Immunexcite Inc. completed an $8.6 million series A-1 financing, topping off a series of smaller rounds that sustained the immuno-oncology (I-O) company and its technology, dubbed Mabxcite, for more than five years. All told, the Lexington, Mass.-based company has raised more than $15 million since it was incorporated in 2007, mostly beginning with a $2.4 million series A at the end of 2011.